Stockhead | Biocurious: Lumos shines a light on the post-pandemic rapid diagnosis sector
30 April 2025
Lumos was recently featured in this insightful Stockhead article by business journalist Tim Boreham.
The piece outlines how the Company is positioning itself in the rapidly growing point-of-care diagnostics sector, detailing their progress with Medicare reimbursement and BARDA-funded clinical trials, and how FebriDx is driving growth for the Company.
Here’s an excerpt:
“FebriDx offers the strongest growth prospects in a world in which clinicians and patients want an answer now, rather than when the lab decides to return a result.
Research platform MST Access says: “the global healthcare system increasingly is prioritising rapid diagnostic solutions, particularly in infectious disease management and antibiotic stewardship.
“Lumos’s proprietary technology addresses this need with point-of-care solutions that reduce the time to diagnosis and treatment.”
Click to read the full analysis.
The piece outlines how the Company is positioning itself in the rapidly growing point-of-care diagnostics sector, detailing their progress with Medicare reimbursement and BARDA-funded clinical trials, and how FebriDx is driving growth for the Company.
Here’s an excerpt:
“FebriDx offers the strongest growth prospects in a world in which clinicians and patients want an answer now, rather than when the lab decides to return a result.
Research platform MST Access says: “the global healthcare system increasingly is prioritising rapid diagnostic solutions, particularly in infectious disease management and antibiotic stewardship.
“Lumos’s proprietary technology addresses this need with point-of-care solutions that reduce the time to diagnosis and treatment.”
Click to read the full analysis.
